Which cholinergic symptoms of parkinson’s disease are reduced with anticholinergic drugs?
Medication SummaryThe cornerstone of symptomatic treatment for Parkinson disease (PD) is dopamine replacement therapy. The criterion standard of symptomatic therapy is levodopa (L-dopa), the metabolic precursor of dopamine, in combination with carbidopa, a peripheral decarboxylase inhibitor (PDI). This combination provides the greatest symptomatic benefit with the fewest short-term adverse effects. Show
Dopamine agonists such as pramipexole and ropinirole can be used as monotherapy to improve symptoms in early disease or as adjuncts to levodopa in patients whose response to levodopa is deteriorating and in those who are experiencing fluctuations in their response to levodopa. Monoamine oxidase (MAO)-B inhibitors (eg, rasagiline, safinamide, selegiline) provide symptomatic benefit as monotherapy in early disease and as adjuncts to levodopa in patients experiencing motor fluctuations. Catechol-O -methyl transferase (COMT) inhibitors (eg, entacapone, tolcapone, opicapone) may be used to increase the peripheral half-life of levodopa, thereby delivering more levodopa to the brain over a longer time. Anticholinergic medications can be used for the treatment of resting tremor. However, they are not particularly effective for bradykinesia, rigidity, gait disturbance, or other features of advanced Parkinson disease; and cognitive side effects are common. Therefore anticholinergics are usually reserved for the treatment of tremor that is not adequately controlled with dopaminergic medications. Pimavanserin is the first medication approved by the FDA for hallucinations and delusions associated with PD. It is a selective serotonin inverse agonists (SSIA) which preferentially targets 5-HT2A receptors and avoids activity at dopamine and other receptors commonly targeted by antipsychotics. Dopamine AgonistsClass SummaryDopamine agonists are effective as monotherapy in early PD and as adjuncts to levodopa/PDI (peripheral decarboxylase inhibitor) in moderate to advanced disease. Dopamine agonists directly stimulate postsynaptic dopamine receptors to provide antiparkinsonian benefit. All available dopamine agonists stimulate D2 receptors, an action that is thought to be clinically beneficial. The role of other dopamine receptors is currently unclear. Dopamine agonists are effective to treat motor features of early PD, and they cause less development of motor fluctuations and dyskinesia than levodopa. For patients with motor fluctuations on levodopa/PDI, the addition of a dopamine agonist reduces off time, improves motor function, and allows lower levodopa doses. Carbidopa/levodopa (Sinemet, Sinemet CR, Rytary, Duopa)
Carbidopa/levodopa is approved for the treatment of symptoms of idiopathic PD, postencephalitic parkinsonism, and symptomatic parkinsonism that may follow injury to the nervous system by carbon monoxide and/or manganese intoxication. Levodopa, combined with a peripheral decarboxylase inhibitor (PDI) such as carbidopa, is the criterion standard of symptomatic treatment for PD; it provides the greatest antiparkinsonian efficacy in moderate to advanced disease with the fewest acute adverse effects. When administered alone, levodopa causes a high incidence of nausea and vomiting due to the formation of dopamine in the peripheral circulation. Carbidopa inhibits the decarboxylation of levodopa to dopamine in the peripheral circulation thereby reducing nausea and allowing for greater levodopa distribution into the CNS. Carbidopa does not cross the blood-brain barrier. Sustained-release capsules (Rytary) may improve drug delivery for patients unable to swallow effectively. The capsule may be either swallowed whole or opened and sprinkled on a small amount of applesauce for immediate consumption. An enteral suspension (Duopa) is administered by a portable pump into the jejunum over a 16-hr period to improve on-time and decrease off-time in patients with motor fluctuations with advanced Parkinson disease. Levodopa inhaled (Inbrija)
Powder for inhalation is systemically absorbed via lungs, and therefore bypasses GI absorption, which may be variable in patients with PD. Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and is converted to dopamine in the brain. It is indicated for intermittent treatment of "off" episodes in patients with Parkinson disease who are taking oral carbidopa/levodopa. Apomorphine (Apokyn, Kynmobi)
Apomorphine is a nonergoline dopamine agonist indicated for the acute, intermittent treatment of hypomobility "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) associated with advanced PD. It is administered by a subcutaneous injection or sublingual. Although the exact mechanism by which apomorphine exerts its therapeutic effects in PD is unknown, it is thought to occur via activation of postsynaptic D2 receptors in the striatum. Initial dose and dose titration must be administered by a healthcare provider. Pramipexole (Mirapex, Mirapex ER)
Pramipexole is approved as monotherapy in early disease and as adjunctive therapy to levodopa/PDI in more advanced stages. The mechanism of action of pramipexole as a treatment for PD is unknown, although it is believed to be related to its ability to stimulate D2 dopamine receptors in the striatum. It is available as an immediate-release and an extended-release tablet. Ropinirole (Requip and Requip XL)
Ropinirole is approved as monotherapy in early disease and as adjunctive therapy to levodopa/PDI in more advanced disease. Ropinirole is a nonergot dopamine agonist that has high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors; it binds with higher affinity to D3 than to D2 or D4 receptor subtypes. The mechanism of action of ropinirole is stimulation of dopamine D2 receptors in striatum. It is available as an immediate-release and an extended-release tablet. Amantadine (Gocovri)
Amantadine is approved for the treatment of idiopathic PD, postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication. The extended-release capsule is indicated for dyskinesia in patients with PD. Amantadine is available as a syrup, tablet, capsule, and an extended-release capsule. The exact mechanism of amantadine for the treatment of PD and dyskinesia associated with PD is unknown. Amantadine is a weak, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Rotigotine (Neupro)
Dopamine agonist stimulating D3, D2, and D1 receptors. Improvement in Parkinson-related symptoms thought to be its ability to stimulate D2 receptors within the caudate putamen in the brain. Indicated for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD). Dosage ranges differ for early-stage PD and advanced-stage PD. Available as transdermal patch that provides continuous delivery for 24 h AnticholinergicClass SummaryAnticholinergics are commonly used as symptomatic treatment of PD, both as monotherapy and as part of combination therapy. Anticholinergic agents provide benefit for tremor in approximately 50% of patients but do not substantially improve bradykinesia or rigidity. If one anticholinergic does not work, try another. Trihexyphenidyl
Trihexyphenidyl is indicated as an adjunct for all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. It is a synthetic tertiary amine anticholinergic agent. It has a direct antispasmodic action on smooth muscle and has weak mydriatic, antisecretory, and positive chronotropic activities. In addition to suppressing central cholinergic activity, trihexyphenidyl may also inhibit reuptake and storage of dopamine at central dopamine receptors, thereby prolonging the action of dopamine. It is commonly used in combination with other antiparkinsonian agents. Generally, anticholinergic agents can help control tremor but are less effective for treating bradykinesia or rigidity. Benztropine mesylate (Cogentin)
Benztropine mesylate is approved for use as an adjunct in the therapy of all forms of PD. It partially blocks striatal cholinergic receptors, and by blocking muscarinic cholinergic receptors in the CNS, benztropine reduces the excessive cholinergic activity present in parkinsonism and related states. It can also block dopamine reuptake and storage in CNS cells. In general, anticholinergic agents can help control tremor but are less effective for treating bradykinesia or rigidity. MAO-B inhibitorsClass SummaryMAO-B inhibitors inhibit the activity of MAO-B oxidases that are responsible for inactivating dopamine. Selegiline (Eldepryl, Zelapar)
Selegiline is approved as adjunctive therapy to levodopa/carbidopa in patients who exhibit deterioration in response to that therapy. For patients who are experiencing motor fluctuations on levodopa/carbidopa, the addition of selegiline reduces off time, improves motor function, and allows levodopa dose reductions. If a patient experiences an increase in troublesome dyskinesia, reduce the levodopa dose. Selegiline blocks the breakdown of dopamine and extends the duration of action of each dose of levodopa. Rasagiline (Azilect)
Rasagiline is indicated for the treatment of the signs and symptoms of idiopathic PD as initial monotherapy and as adjunctive therapy to levodopa. Rasagiline is an irreversible MAO-B inhibitor that blocks dopamine degradation. Rasagiline at a dosage of 1 mg once daily is given as monotherapy. When it is given as adjunctive therapy, an initial dose of 0.5 mg once daily is administered. Dosage adjustments are required if clinical response is not seen. Safinamide (Xadago)
Safinamide inhibits MAO-B activity, by blocking the catabolism of dopamine. It is indicated as add-on treatment for patients with Parkinson disease who are currently taking levodopa/carbidopa and experiencing “off” episodes. Acetylcholinesterase Inhibitors, CentralClass SummaryPathologic changes in dementia associated with PD involve cholinergic neuronal pathways that project from the basal forebrain to the cerebral cortex and hippocampus. These pathways may be involved in memory, attention, learning, and other cognitive processes. Acetylcholinesterase inhibitors may exert their therapeutic effect by enhancing cholinergic function through inhibition of acetylcholinesterase. Donepezil (Aricept)
Donepezil is a reversible inhibitor of ACh and exerts its beneficial effects by enhancing cholinergic function. It is indicated for the treatment for dementia of the Alzheimer type. Rivastigmine (Exelon)
Rivastigmine is indicated for the treatment of mild to moderate dementia associated with PD. In addition, it is also approved for the treatment of mild to moderate dementia of the Alzheimer type. Rivastigmine is a selective, competitive, and reversible acetylcholinesterase (ACh) inhibitor. It may reversibly inhibit cholinesterase, which may, in turn, increase concentrations of ACh available for synaptic transmission in CNS and thereby enhance cholinergic function. The effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. It is available as a capsule and an extended-release transdermal. Galantamine (Razadyne, Razadyne ER)
Galantamine is a competitive and reversible inhibitor of ACh. It is approved for the treatment of mild to moderate dementia of the Alzheimer type. NMDA AntagonistsClass SummaryPersistent activation of CNS N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of dementia. Agents such as memantine, which is an NMDA receptor antagonist, can prevent activation of the NMDA receptors. Memantine (Namenda, Namenda XR)
Memantine is approved for the treatment of moderate to severe dementia in Alzheimer disease. Initial dosage is 5 mg once daily for immediate-release tablets and 7 mg once daily for extended-release tablets. Dosage titration may be required based on clinical response. Memantine is postulated to exert its therapeutic effect through its action as a low- to moderate-affinity, uncompetitive NMDA receptor antagonist. Blockade of NMDA receptors by memantine slows the intracellular calcium accumulation and helps prevent further nerve damage. COMT InhibitorsClass SummaryCatechol-O -methyl transferase (COMT) inhibitors inhibit the peripheral metabolism of levodopa, making more levodopa available for transport across the blood-brain barrier over a longer time. For patients with motor fluctuations on levodopa/carbidopa, the addition of a COMT inhibitor decreases off time, improves motor function, and allows lower levodopa doses. Opicapone (Ongentys)
Once daily, peripheral-acting, COMT inhibitor that decreases conversion rate of levodopa to 3-O-methyldopa, thereby prolonging levodopa half-life to reduce motor fluctuations. It is indicated as an adjunct to levodopa/carbidopa to reduce OFF episodes in patients with Parkinson disease. Entacapone (Comtan)
Entacapone is approved as an adjunct to levodopa/carbidopa for patients who are experiencing signs and symptoms of end-of-dose "wearing-off." The mechanism of action of entacapone is related to its ability to inhibit COMT and alter plasma pharmacokinetics of levodopa. When given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor (eg, carbidopa), plasma levels of levodopa are more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. These sustained plasma levels of levodopa may result in more constant dopaminergic stimulation in the brain. This may lead to greater effects on signs and symptoms of PD, as well as increased levodopa adverse effects (which sometimes require a levodopa dose decrease). Carbidopa, levodopa, and entacapone (Stalevo)
Carbidopa/levodopa/entacapone is indicated for the treatment of PD to substitute (with equivalent strengths of each of the 3 components) for immediate-release carbidopa/levodopa and entacapone previously administered as individual products. It is also used to replace immediate-release carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose "wearing-off" (only for patients taking a total daily dose of levodopa of 600 mg or less and not experiencing dyskinesias). Carbidopa inhibits dopa decarboxylation, thereby allowing more complete levodopa distribution to the CNS. Levodopa is a dopamine precursor capable of crossing the blood-brain barrier, thereby increasing CNS dopamine following conversion. Entacapone inhibits COMT, another enzyme that metabolizes levodopa. COMT inhibition increases and sustains levodopa plasma levels, enabling more blood-brain barrier penetration. Tolcapone (Tasmar)
Tolcapone is an adjunct to levodopa/carbidopa therapy in PD in patients who are experiencing motor fluctuations. Because of the risk of hepatotoxicity, tolcapone is reserved for patients who have not responded adequately to, or are not appropriate candidates for, other adjunctive medications. If improvement is not apparent within 3 weeks, this medication should be withdrawn. Tolcapone is a selective and reversible inhibitor of COMT. In the presence of a decarboxylase inhibitor such as carbidopa, COMT is the major degradation pathway for levodopa. By inhibiting COMT, there are more sustained plasma levels of levodopa, as well as enhanced central dopaminergic activity. Selective Serotonin Inverse Agonists (SSIA)Class SummarySSIAs preferentially target 5-HT2A receptors, but does not affect activity of dopamine and other receptors commonly targeted by antipsychotics. Pimavanserin (Nuplazid)
Pimavanserin is an SSIA which preferentially targets 5-HT2A receptors and avoids activity at dopamine and other receptors commonly targeted by antipsychotics. It is indicated for hallucinations and delusions associated with PD. Adenosine AntagonistsClass SummaryOption for adjunctive use with levodopa/carbidopa to reduce Parkinson disease OFF episodes. Istradefylline (Nourianz)
Selective adenosine A2A receptor antagonist. Precise mechanism by which it reduces OFF episodes is unknown. Istradefylline is indicated as adjunctive treatment to levodopa/carbidopa in adults with PD experiencing OFF episodes.
Author Robert A Hauser, MD, MBA Professor of Neurology, Molecular Pharmacology and Physiology, Director, USF Parkinson's Disease and Movement Disorders Center, National Parkinson Foundation Center of Excellence, Byrd Institute, Clinical Chair, Signature Interdisciplinary Program in Neuroscience, University of South Florida College of Medicine Robert A Hauser, MD, MBA is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Society of Neuroimaging, International Parkinson and Movement Disorder Society Disclosure: Received consulting fee from Cerecor for consulting; Received consulting fee from L&M Healthcare for consulting; Received consulting fee from Cleveland Clinic for consulting; Received consulting fee from Heptares for consulting; Received consulting fee from Gerrson Lehrman Group for consulting; Received consulting fee from Indus for consulting; Received consulting fee from University of Houston for consulting; Received consulting fee from AbbVie for consulting; Received consulting fee from Adama. Coauthor(s) Kelly E Lyons, PhD Research Professor of Neurology, Director of Research and Education, Parkinson’s Disease and Movement Disorder Center, University of Kansas Medical Center Kelly E Lyons, PhD is a member of the following medical societies: American Academy of Neurology, International Parkinson and Movement Disorder Society Disclosure: Received honoraria from Novartis for speaking and teaching; Received honoraria from Teva Neuroscience for speaking and teaching; Received honoraria from St Jude Medical for board membership. Theresa A McClain, RN, MSN, ARNP-BC Advanced Registered Nurse Practitioner and Investigator, Parkinson’s Disease and Movement Disorders Center, University of South Florida College of Medicine Theresa A McClain, RN, MSN, ARNP-BC is a member of the following medical societies: Sigma Theta Tau International Disclosure: Received consulting fee from Teva for consulting; Received consulting fee from Schering Plough for consulting; Received consulting fee from Biotie for consulting; Received consulting fee from Novartis for consulting. Chief Editor Selim R Benbadis, MD Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida Morsani College of Medicine Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, American Medical Association Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Aquestive, Bioserenity, Ceribell, Eisai, Jazz, LivaNova, Neurelis, Neuropace, Nexus, SK life science, Stratus, Sunovion, UCB Acknowledgements Ron L Alterman, MD Associate Professor of Neurosurgery, Mount Sinai School of Medicine; Consulting Surgeon, Department of Neurosurgery, Mount Sinai School of Medicine, Elmhurst Hospital, and Walter Reed Army Medical Center Ron L Alterman, MD is a member of the following medical societies: Alpha Omega Alpha, American Association of Neurological Surgeons, Congress of Neurological Surgeons, Medical Society of the State of New York, and New York County Medical Society Disclosure: Nothing to disclose. Heather S Anderson, MD Assistant Professor, Staff Neurologist, Department of Neurology, Alzheimer and Memory Center, University of Kansas Medical Center Heather S Anderson, MD is a member of the following medical societies: American Academy of Neurology Disclosure: Nothing to disclose. Jeff Blackmer, MD, FRCP(C) Associate Professor, Medical Director, Neurospinal Service, Division of Physical Medicine and Rehabilitation, The Rehabilitation Centre, University of Ottawa Faculty of Medicine; Executive Director, Office of Ethics, Canadian Medical Association Jeff Blackmer, MD, FRCP(C) is a member of the following medical societies: American Paraplegia Society, Canadian Association of Physical Medicine and Rehabilitation, Canadian Medical Association, and Royal College of Physicians and Surgeons of Canada Disclosure: Nothing to disclose. Thomas L Carroll, MD Assistant Professor, Department of Otolaryngology-Head and Neck Surgery, Tufts University School of Medicine and Director, The Center for Voice and Swallowing, Tufts Medical Center Thomas L Carroll, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Otolaryngology-Head and Neck Surgery, American Bronchoesophagological Association, American Laryngological Association, and American Medical Association Disclosure: Merz aesthetics inc. Consulting fee Speaking and teaching Richard J Caselli, MD Professor, Department of Neurology, Mayo Medical School, Rochester, MN; Chair, Department of Neurology, Mayo Clinic of Scottsdale Richard J Caselli, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Medical Association, American Neurological Association, and Sigma Xi Disclosure: Nothing to disclose. Arif I Dalvi, MD Director, Movement Disorders Center, NorthShore University HealthSystem, Clinical Associate Professor of Neurology, University of Chicago Pritzker Medical School Arif I Dalvi, MD is a member of the following medical societies: European Neurological Society and Movement Disorders Society Disclosure: Nothing to disclose. Nestor Galvez-Jimenez, MD, MSc, MHA Chairman, Department of Neurology, Program Director, Movement Disorders, Department of Neurology, Division of Medicine, Cleveland Clinic Florida Nestor Galvez-Jimenez, MD, MSc, MHA is a member of the following medical societies: American Academy of Neurology, American College of Physicians, and Movement Disorders Society Disclosure: Nothing to disclose. Stephen T Gancher, MD Adjunct Associate Professor, Department of Neurology, Oregon Health Sciences University Stephen T Gancher, MD is a member of the following medical societies: American Academy of Neurology, American Neurological Association, and Movement Disorders Society Disclosure: Nothing to disclose. Michael Hoffmann, MBBCh, MD, FCP(SA), FAAN, FAHA Professor of Neurology, University of Central Florida College of Medicine; Director of Cognitive Neurology, Director of Stroke Program, James A Haley Veterans Affairs Hospital Michael Hoffmann, MBBCh, MD, FCP(SA), FAAN, FAHA is a member of the following medical societies: American Academy of Neurology, American Headache Society, American Heart Association, and American Society of Neuroimaging Disclosure: Nothing to disclose. Daniel H Jacobs MD, FAAN, Associate Professor of Neurology, University of Florida College of Medicine; Director for Stroke Services, Orlando Regional Medical Center Daniel H Jacobs is a member of the following medical societies: American Academy of Neurology, American Society of Neurorehabilitation, and Society for Neuroscience Disclosure: Teva Pharmaceutical Grant/research funds Consulting; Biogen Idex Grant/research funds Independent contractor; Serono EMD Royalty Speaking and teaching; Pfizer Royalty Speaking and teaching; Berlex Royalty Speaking and teaching Robert M Kellman, MD Professor and Chair, Department of Otolaryngology and Communication Sciences, State University of New York Upstate Medical University Robert M Kellman, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Medical Association, American Neurotology Society, American Rhinologic Society, American Society for Head and Neck Surgery, Medical Society of the State of New York, and Triological Society Disclosure: GE Healthcare Honoraria Review panel membership; Revent Medical Honoraria Review panel membership Milton J Klein, DO, MBA Consulting Physiatrist, Heritage Valley Health System-Sewickley Hospital and Ohio Valley General Hospital Milton J Klein, DO, MBA is a member of the following medical societies: American Academy of Disability Evaluating Physicians, American Academy of Medical Acupuncture, American Academy of Osteopathy, American Academy of Physical Medicine and Rehabilitation, American Medical Association, American Osteopathic Association, American Osteopathic College of Physical Medicine and Rehabilitation, American Pain Society, and Pennsylvania Medical Society Disclosure: Nothing to disclose. Kat Kolaski, MD Assistant Professor, Departments of Orthopedic Surgery and Pediatrics, Wake Forest University School of Medicine Kat Kolaski, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine and American Academy of Physical Medicine and Rehabilitation Disclosure: Nothing to disclose. Jose G Merino, MD Medical Director, Suburban Hospital Stroke Program Jose G Merino, MD is a member of the following medical societies: American Heart Association and American Stroke Association Disclosure: Nothing to disclose. Arlen D Meyers, MD, MBA Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society Disclosure: Covidien Corp Consulting fee Consulting; US Tobacco Corporation Unrestricted gift Unknown; Axis Three Corporation Ownership interest Consulting; Omni Biosciences Ownership interest Consulting; Sentegra Ownership interest Board membership; Syndicom Ownership interest Consulting; Oxlo Consulting; Medvoy Ownership interest Management position; Cerescan Imaging Honoraria Consulting; GYRUS ACMI Honoraria Consulting Lorraine Ramig, PhD Professor, Department of Speech Language Hearing Sciences, University of Colorado at Boulder; Senior Scientist, National Center for Voice and Speech (NCVS); Adjunct Professor, Department of Biobehavior, Columbia University Teacher's College Disclosure: Nothing to disclose. Alan D Schmetzer, MD Professor Emeritus, Interim Chairman, Vice-Chair for Education, Associate Residency Training Director in General Psychiatry, Fellowship Training Director in Addiction Psychiatry, Department of Psychiatry, Indiana University School of Medicine; Addiction Psychiatrist, Midtown Mental Health Cener at Wishard Health Services Alan D Schmetzer, MD is a member of the following medical societies: American Academy of Addiction Psychiatry, American Academy of Clinical Psychiatrists, American Academy of Psychiatry and the Law, American College of Physician Executives, American Medical Association, American Neuropsychiatric Association, American Psychiatric Association, and Association for Convulsive Therapy Disclosure: Eli Lilly & Co. Grant/research funds Other Roy Sucholeiki, MD Director, Comprehensive Seizure and Epilepsy Program, The Neurosciences Institute at Central DuPage Hospital Roy Sucholeiki, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, and American Neuropsychiatric Association Disclosure: Nothing to disclose. Margaret M Swanberg, DO Assistant Professor of Neurology, Uniformed Services University; Chief of Neurobehavior Service, Walter Reed Army Medical Center; Assistant Chief, Department of Neurology, Walter Reed Army Medical Center Margaret M Swanberg, DO is a member of the following medical societies: American Academy of Neurology and American Neuropsychiatric Association Disclosure: Nothing to disclose. Michele Tagliati, MD Associate Professor, Department of Neurology, Mount Sinai School of Medicine; Division Chief of Movement Disorders, Mount Sinai Medical Center Michele Tagliati, MD is a member of the following medical societies: American Academy of Neurology, American Medical Association, and Movement Disorders Society Disclosure: Nothing to disclose. Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference Disclosure: Medscape Salary Employment B Viswanatha, MBBS, MS, DLO Professor of Otolaryngology (ENT), Chief of ENT III Unit, Sri Venkateshwara ENT Institute, Victoria Hospital, Bangalore Medical College and Research Institute; PG and UG Examiner, Manipal University, India and Annamalai University, India B Viswanatha, MBBS, MS, DLO is a member of the following medical societies: Association of Otolaryngologists of India, Indian Medical Association, and Indian Society of Otology Disclosure: Nothing to disclose. Which of the following symptoms of parkinsonism can be relieved by anticholinergics?Anticholinergics may be used as an additional treatment to help relieve the tremor of PD.
What are the symptoms of cholinergic Parkinson's disease?In Parkinson's disease (PD), disruption of central cholinergic transmission has been associated with cognitive decline, gait problems, freezing of gait (FOG), falls, REM sleep behavior disorder (RBD), neuropsychiatric manifestations, and olfactory dysfunction.
What are the 4 main uses of anticholinergic drugs?Doctors prescribe anticholinergic drugs to treat a variety of conditions, including chronic obstructive pulmonary disease (COPD), bladder conditions, gastrointestinal disorders, and symptoms of Parkinson's disease.
|